Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of $4.5B as of December 31, 2025, supporting cash runway into profitability.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Priovant reports Phase 2 results for brepocitinib in cutaneous sarcoidosis
- ROIV Earnings this Week: How Will it Perform?
- The Week That Was, The Week Ahead: Macro and Markets, Feb. 1
- M&A News: India’s Sun Pharma Eyes $10B Bid for U.S.’ Organon
- Roivant Sciences price target raised to $28 from $25 at Guggenheim